Imunon Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
RESEARCH AND DEVELOPMENT EXPENDITURES
We are engaged in a limited amount of research and development in our own facilities and have sponsored research programs in partnership with various research institutions, including the NIH, the Wistar Institute and Acuitas Therapeutics. The majority of the spending in research and development is for the funding of IMNN-001 clinical trials and our next generation vaccine initiative. Research and development expenses were approximately $11.3 million and $11.7 million for the years ended December 31, 2023 and 2022, respectively. SeePart II, Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operationsof this Annual Report for additional information regarding expenditures related to our research and development programs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.